The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
From the IHC RNS,
"Neil Campbell, Chief Executive Officer of Inspiration Healthcare commented "We are delighted to be able to work with genedrive plc with this novel testing device for new born babies that could suffer hearing loss due to anti-biotics given to them on admission into neonatal intensive care. Our focus has always been products that can have a profound effect on the patient outcome and we look forward to working with genedrive to make this test the standard of care in the UK and the wider neonatal community around the world."
"David Budd, Chief Executive Officer of genedrive plc, said: "Our agreement with Inspiration Healthcare combines genedrive's innovative first-to-market AIHL product, with a thought leading healthcare company with a specialist emphasis on neonatal care. Inspiration Healthcare has a strong track record in the introduction of new technologies and over many years they have developed an extensive network of key opinion leaders that will be very beneficial as we bring the Genedrive AIHL test to market together."
This was in the Genedrive placing RNS today, note the projected revenues for this test.
"Antibiotic-Induced Hearing Loss ("AIHL")
Around one in 500 infants carry a genetic mutation that's puts them at risk of suffering lifelong profound hearing loss after exposure to gentamycin, a commonly used antibiotic. genedrive has developed world's first rapid point-of-care genetic test for neonatal intensive care. There are no other point-of-care tests commercially available for AIHL and the Directors believe genedrive's test could support a new standard of care for all urgent case infants.
genedrive's AIHL test has a high clinical accuracy with 100% sensitivity and 100% specificity. Implementation trials for the test are progressing at Manchester and Liverpool but, as announced on 25 March 2020, have not been able to continue at the same pace as previous months as a result of NHS resources being diverted to address COVID-19.
On 24 April 2020, genedrive announced that it had entered into a distribution agreement with Inspiration Healthcare Group plc for the distribution of genedrive's AIHL test in the UK and Ireland. The Directors estimate the UK and global markets for this test to be worth up to £3.5 million and £35 million per year, respectively, to genedrive based on a price of £2,000 per Genedrive® unit and £35 per test."
There were two 55k trades on the 27th and 28th of last month as well.
Looks like lots of small sells being squeezed out by the price action and big lumpy trades picking them up.
pending news of the next nhs order
IHC is an investment and will deliver good results this year; however its an investment and impatient PIs are moving money elsewhere seeking quicker (but riskier) returns. I reckon this will hit 90-100p later this year on results. Could however do with a bit of friendly media coverage, just seems completely off people's radar.
this has not moved since its first NHS order a mth ago....
is the market saying this going down ?? time will tell..
good luck all...the lack of movment as put it on everyones radar...
not sure if its for a rise or drop to buy into...
There are lots of trading stock to play with at the moment, great fun when they go up, not so great when they go down. So a sensible approach is to play with some of your capital and also note the Companies that are going to grow in the long term (Investments).
Lockdown has given us the next dotcom boom, plenty of people thinking they are trading geniuses, it isn't too hard to pick a stock and ride the wave, but there will be some almighty falls, where some will lose their shirts as they over extend as the SP's rise.
We haven't been long into this crisis, but we have already seen ventilator manufacturers be told their product isn't up to scratch or is no longer needed. Testing has now become the new goldmine, but just like ventilators, many tests won't get approval and once the big boys get their tests and vaccines in the market the smaller companies will find they are sidelined. Collaborations may help, but nothing is certain.
If and when a vaccine is produced then tests for COVID19 will cease to be needed in any large number. In the meantime some of these smaller companies are neglecting their other products, R&D, sales and marketing. So there will be positive and negative balances and only the ones who successfully monetise any COVID offering will have the positives to balance and hopefully outweigh the negatives....
GDR is where all the money is …
just look at the daily trades... this rarely shifts even with an rns..
gdr up 50% in the last week
Well there is still a buying op here, as others chase rainbows elsewhere.
This is confirmation of the start of delivery of concrete NHS orders that the Company have received.... £5.25m in total....
Also cannot emphasize enough the 24 hour helpline, this will put Inspiration Healthcare at the forefront of the minds of all the frontline staff in these critical care settings all over the country.
"In the last few days, Inspiration Healthcare has also extended its 24 hour helpline facility to give clinical staff at all UK hospitals access to qualified personnel employed by Inspiration who are able to give instructions on setting up of ventilators correctly and also to deal with any other issues which may arise during their use"
Well it would seem to be encouraging sellers and discouraging buyers, but it is certainly making the situation far from transparent. We have to remember they had some recent spikes and the MMs may still have be short on their book so they need more stock before releasing it.
If you look at the 6 month chart you can see that the past 6 weeks resembles a coiled spring, with a clear downtrend from the spikes and a clear uptrend from the troughs, these lines are rapidly converging and at one point the SP will have to attempt to breakout of this pattern.
Bit out of my comfort zone regarding the games the MMs play. What will be the result of this?
I have been watching this for a few days now, loads of small sells, often matched with larger buys, the 55k trade looked like it was filled from the small sellers.
Looking at the chart I see 60p level as one where the the price should bounce, there have been a lot more bigger buys today (they don't seem to come into the trades data on this site - delayed, trades, mid price let alone the usual buys below mid price).
On that note it is 60.4p to buy even with the tick ups, 60.3p to sell so very tight spread and buys can take advantage. MMs seem to want to put a lid on buying with the false wide spread...
I too am surprised it hasn't increased. The recent RNS was extremely positive and the price barely shifted!
Surprised it hasn't gone up more considering the majority of their revenue comes from a and e consumables.
Looks like a bargain at the current SP level, strong business with a good balance sheet and profitable in the right sector selling essentials and regular RNS updates
Starting to shift now. Gdr may use for covid test distribution also. Very good results into the bargain.atb
Oh there it is...
Bit weird my BUY isn’t showing
Just got 10k @ £63.99. A little bit higher than I wanted but couldn’t wait any longer as this is hopefully going to take off.
Thanks Beamer I was more after LTH shareholder sentiment. I see revenue growth of 18% and the NHS contracts over ventilator supply which is understandable, but are most holders here long term holders? I'm guessing that's the case because of the type of 'steady business' this is and so must be happy generally with the performance year on year.
A quick flick through recent RNS’s will tell you all you need to know
Final results released just this week and some blockbuster contracts with the NHS
Hello, I am a long term holder in Genedrive and noticed the RNS this morning. I had not heard of Inspiration before and am considering investing. Please can I ask LTH for views of the business and where growth will come from? Is this an AIM or fully listed? Thank you everyone
That's a potential 4 bags
"It is worth noting that based on Cenkos’ analysis, Inspiration is significantly undervalued trading on a forward enterprise multiple (EV/EBITDA) of 6.8-times compared with a sector average of 25.9-times. "
https://www.proactiveinvestors.co.uk/companies/news/917763/inspiration-healthcare-makes-progress-on-three-strategic-fronts-917763.html